"Cytochrome P-450 CYP2C9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 subtype that has specificity for acidic XENOBIOTICS. It oxidizes a broad range of important clinical drugs that fall under the categories of NONSTEROIDAL ANTI-INFLAMMATORY AGENTS; HYPOGLYCEMIC AGENTS; ANTCOAGULANTS; and DIURETICS.
Descriptor ID |
D065729
|
MeSH Number(s) |
D08.244.453.491.500.500 D08.811.682.690.708.170.450.500.500 D12.776.422.220.453.491.500.500
|
Concept/Terms |
Cytochrome P-450 CYP2C9- Cytochrome P-450 CYP2C9
- CYP2C9, Cytochrome P-450
- Cytochrome P 450 CYP2C9
- P-450 CYP2C9, Cytochrome
- Cytochrome P450 PB-1
- Cytochrome P450 PB 1
- P450 PB-1, Cytochrome
- PB-1, Cytochrome P450
- Cytochrome P450 MP-4
- Cytochrome P450 MP 4
- MP-4, Cytochrome P450
- P450 MP-4, Cytochrome
- Cytochrome P450 MP-8
- Cytochrome P450 MP 8
- MP-8, Cytochrome P450
- P450 MP-8, Cytochrome
- CYP2C9
- CYPIIC9
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C9".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C9".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C9" by people in this website by year, and whether "Cytochrome P-450 CYP2C9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C9" by people in Profiles.
-
Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions. Clin Transl Sci. 2020 09; 13(5):1004-1009.
-
Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system. Pharmacogenet Genomics. 2019 10; 29(8):192-199.
-
Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. Am J Med. 2017 02; 130(2):222-228.
-
Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther. 2014 Jun; 95(6):636-43.
-
Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3):339-43.
-
A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008 Feb; 10(2):89-98.
-
Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):894-901.